Top 10 Prescription Diet Pills That Work Fast
What are the top 10 prescription diet pills that work fast? As obesity has become a real issue of late (more than 2 in 3 adults are considered to be overweight or obese), sometimes...
Posts Tagged ‘Qsymia’
Pharma News: VIVUS, Inc. (VVUS) Qsymia Patents, Arena Pharmaceuticals, Inc. (ARNA) Earnings, Amgen, Inc. (AMGN) Ending an Agreement
Earlier today RFD IP Business Services ("RFD") released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc.
Trending News: Apple Inc (AAPL) and Bank Of America Corp (BAC) Dropping Like Rocks, Here’s Why
Editor's Note: Related tickers: Apple Inc. (NASDAQ:AAPL), Facebook Inc (NASDAQ:FB), Bank of America Corp (NYSE:BAC), Yahoo! Inc. (NASDAQ:YHOO), Cirrus Logic, Inc.
Biopharma News: Theravance Inc (THRX), VIVUS, Inc. (VVUS), Amgen, Inc. (AMGN)
Editor's Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc.
Risks in the Pharma Sector: Amarin, VIVUS and Arena Pharmaceuticals
It has been interesting to note with great fascination the crazy unpredictability in the pharmaceutical sector of the market, most notably Amarin (NASDAQ:AMRN), Arena Pharmaceuticals...
FDA Approval: End of Arena, VIVUS Running Out of Adrenaline?
The celebrations must be over. That was fast. Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS Inc.
Arena Pharmaceuticals vs. Vivus: Which Is a Better Weight Loss Drug for Investors?
Arena Pharmaceuticals (NASDAQ:ARNA) and Vivus (NASDAQ:VVUS) are battling in the minds of investors as each promises a drug with the potential to cause weight loss- a sure moneymaker...
Can Vivus Inc. Ride Qsymia to Market Success and Big Returns?
Since last week's news that Vivus, Inc. (NASDAQ:VVUS) received FDA approval for its obesity drug Qsymia, the raging battle between Vivus and Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.: With Belviq Approval, Now What?
In the pharmaceutical sector of the market, many eyes have been on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and its fierce competitor, Vivus, Inc.
